

Leo I Gordon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7978782/publications.pdf>

Version: 2024-02-01

279
papers

19,307
citations

13827

67
h-index

12558

132
g-index

300
all docs

300
docs citations

300
times ranked

17741
citing authors

#	ARTICLE	IF	CITATIONS
1	Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2022, 197, 71-75.	1.2	6
2	Axicabtagene CiloleuceL as Second-Line Therapy for Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 640-654.	13.9	586
3	Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma. <i>ImmunoTargets and Therapy</i> , 2022, Volume 11, 1-10.	2.7	6
4	NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 322-334.	2.3	35
5	Drug Shortages and Curative Cancer Therapy: The Problem of Dacarbazine and Classical Hodgkin's Lymphoma. <i>JCO Oncology Practice</i> , 2022, , OP2200161.	1.4	0
6	CAR T-cell therapy for relapsed/refractory non-Hodgkin's lymphoma: a comprehensive review.. <i>Clinical Advances in Hematology and Oncology</i> , 2022, 20, 309-318.	0.3	0
7	Lisocabtagene maraleuceL (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6567-6567.	0.8	1
8	Lisocabtagene maraleuceL (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7062-7062.	0.8	4
9	Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , 2021, 137, 1318-1326.	0.6	85
10	Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis. <i>Journal of Biological Chemistry</i> , 2021, 296, 100100.	1.6	23
11	Cardiovascular Toxicities of CAR T-cell Therapy. <i>Current Oncology Reports</i> , 2021, 23, 78.	1.8	10
12	Cachexia is an independent factor for negative clinical and functional outcomes in lymphoma patients receiving CART therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19504-e19504.	0.8	0
13	Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7514-7514.	0.8	5
14	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV+ lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 3493-3500.	0.6	17
15	Safety and Efficacy of Ibrutinib Maintenance (I-M) Following Frontline Induction in Mantle Cell Lymphoma (MCL) with Sequential Assessment of Changes in NGS-MRD. <i>Blood</i> , 2021, 138, 3530-3530.	0.6	0
16	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021, 138, 532-532.	0.6	1
17	<i>In Situ</i> Vaccination with Combination of Class B and Class C Toll-like Receptor 9 Agonist CpG Immune Adjuvant Nanoparticles to Induce a Systemic Anti-Lymphoma Response. <i>Blood</i> , 2021, 138, 2265-2265.	0.6	1
18	Phase I Study of Novel SYK Inhibitor TAK-659 in Combination with R-CHOP for Front-Line Treatment of High Risk Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 3566-3566.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis. <i>Blood</i> , 2021, 138, 231-231.	0.6	2
20	Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial. <i>Blood</i> , 2021, 138, 229-229.	0.6	14
21	Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2-2.	0.6	16
22	TEMPO: A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2021, 138, 3545-3545.	0.6	2
23	Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 30, 102290.	1.7	4
24	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. <i>Lancet, The</i> , 2020, 396, 839-852.	6.3	1,224
25	Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review. <i>EJHaem</i> , 2020, 1, 596-600.	0.4	19
26	A Novel Approach to Safer Glucocorticoid Receptor-Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1898-1908.	1.9	7
27	Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, <i>CDKN2A</i> loss, and <i>TP53</i> mutations: A multi-institutional study. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 484-494.	1.5	14
28	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 3546-3556.	3.2	13
29	Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001. <i>Blood</i> , 2020, 136, 10-11.	0.6	52
30	Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 755-781.	2.3	94
31	PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
32	Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience. <i>Blood</i> , 2020, 136, 14-16.	0.6	1
33	Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease. <i>Blood</i> , 2020, 136, 30-31.	0.6	1
34	In Situ Vaccination in Lymphoma Using Photothermal Therapy with CpG Deoxynucleotide Coated Branched Gold Nanoparticles: Analysis of Tumor Growth and Immune Response in a Murine Xenograft Model. <i>Blood</i> , 2020, 136, 20-21.	0.6	0
35	Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review. <i>Blood</i> , 2020, 136, 9-10.	0.6	3
36	Revving up the immune engine in cHL. <i>Blood</i> , 2019, 134, 1-2.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Biomimetic Magnetic Nanostructures: A Theranostic Platform Targeting Lipid Metabolism and Immune Response in Lymphoma. <i>ACS Nano</i> , 2019, 13, 10301-10311.	7.3	14
38	Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. <i>Leukemia and Lymphoma</i> , 2019, 60, 3266-3271.	0.6	4
39	Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 436-446.	0.4	3
40	Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 45-53.	1.2	25
41	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 1718-1726.	3.2	26
42	Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. <i>Blood</i> , 2019, 134, 241-241.	0.6	89
43	Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7516-7516.	0.8	13
44	Consolidation and maintenance in follicular lymphoma: radioimmunotherapy revisited?. <i>Lancet Haematology</i> , 2018, 5, e96-e97.	2.2	0
45	The impact of fertility preservation on treatment delay and progression-free survival in women with lymphoma: a single-centre experience. <i>British Journal of Haematology</i> , 2018, 180, 901-904.	1.2	11
46	University of Chicago phase II consortium trial of selumetinib (<scp>MEK</scp>i) demonstrates low tolerability and efficacy in relapsed DLBCL. <i>British Journal of Haematology</i> , 2018, 181, 264-267.	1.2	4
47	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.	2.0	47
48	Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 592-603.	1.8	9
49	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3015-3022.	0.8	102
50	Lenalidomide and R-CHOP in follicular lymphoma: where do we go from here?. <i>Lancet Haematology</i> , 2018, 5, e381-e382.	2.2	0
51	Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma. <i>MSphere</i> , 2018, 3, .	1.3	10
52	Getting to transplant in Hodgkin lymphoma: BVB. <i>Blood</i> , 2018, 132, 1-3.	0.6	13
53	<i>In Situ</i> Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. <i>Cancer Discovery</i> , 2018, 8, 1258-1269.	7.7	136
54	Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7505-7505.	0.8	130

#	ARTICLE	IF	CITATIONS
55	Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.. Journal of Clinical Oncology, 2018, 36, 7541-7541.	0.8	4
56	High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND) Tj ETQq0 0 0 rgBT /Overlock 10 administration.. Journal of Clinical Oncology, 2018, 36, 120-120.	0.8	23
57	Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells. Oncotarget, 2018, 9, 21166-21181.	0.8	12
58	Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study.. Journal of Clinical Oncology, 2018, 36, 7540-7540.	0.8	1
59	Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy. Current Treatment Options in Oncology, 2017, 18, 11.	1.3	22
60	Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. British Journal of Haematology, 2017, 177, 72-79.	1.2	7
61	Impact of cachexia on outcomes in aggressive lymphomas. Annals of Hematology, 2017, 96, 951-956.	0.8	30
62	Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 716-718.	2.3	0
63	Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 608-638.	2.3	81
64	Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. Journal of Allergy and Clinical Immunology, 2017, 140, 875-879.e1.	1.5	42
65	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. Cell, 2017, 171, 481-494.e15.	13.5	804
66	Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors. Clinical Medicine Insights: Oncology, 2017, 11, 117955491773107.	0.6	14
67	Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin. Molecular Pharmaceutics, 2017, 14, 4042-4051.	2.3	33
68	GSK-3 β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. Oncotarget, 2017, 8, 114924-114934.	0.8	20
69	CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).. Journal of Clinical Oncology, 2017, 35, 7513-7513.	0.8	24
70	Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. Oncotarget, 2017, 8, 11219-11227.	0.8	21
71	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1067-1079.	2.3	107
72	High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1274-1281.	2.3	7

#	ARTICLE	IF	CITATIONS
73	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , 2016, 128, 2489-2496.	0.6	370
74	PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher. <i>Expert Review of Hematology</i> , 2016, 9, 939-949.	1.0	13
75	Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). <i>Cancer</i> , 2016, 122, 2996-3004.	2.0	31
76	Diffuse Large B-Cell Lymphoma Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 196-231.	2.3	76
77	Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL). <i>Cancer Biology and Therapy</i> , 2016, 17, 300-309.	1.5	33
78	A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 1059-1066.	3.2	71
79	SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial. <i>Blood</i> , 2016, 128, 2974-2974.	0.6	13
80	Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. <i>Blood</i> , 2016, 128, 624-624.	0.6	8
81	Bevacizumab for recurrent primary central nervous system lymphoma: a new treatment?. <i>Neuro-Oncology</i> , 2015, 17, 1648-1649.	0.6	2
82	Hodgkin Lymphoma, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 554-586.	2.3	37
83	Evaluation of the International Prognostic Score (IPS) and a Simpler Prognostic Score (IPS) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015, 171, 530-538.	1.2	54
84	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942.	0.8	33
85	Anti-CD20 single chain variable antibody fragment-apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas. <i>Biochemistry and Cell Biology</i> , 2015, 93, 343-350.	0.9	14
86	Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e157-e162.	0.2	15
87	Synthetic high-density lipoprotein-like nanoparticles for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 27-34.	1.1	25
88	Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy. <i>Blood Reviews</i> , 2015, 29, 25-32.	2.8	38
89	Synthetic High-Density Lipoprotein-Like Nanoparticles as Cancer Therapy. <i>Cancer Treatment and Research</i> , 2015, 166, 129-150.	0.2	53
90	Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. <i>Blood</i> , 2015, 126, 2693-2693.	0.6	8

#	ARTICLE	IF	CITATIONS
91	Scavenger Receptor Type B1 Is Essential for High Density Lipoprotein Nanoparticle Induced B-Cell Lymphoma Cell Death. <i>Blood</i> , 2015, 126, 2756-2756.	0.6	1
92	Synthetic High-Density Lipoprotein-like Nanoparticles (HDL NP) Cause Apoptosis and Enhance Killing By B-Cell Receptor and BCL-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2949-2949.	0.6	0
93	Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial. <i>Blood</i> , 2015, 126, 3990-3990.	0.6	0
94	Functional Characterization of NAD Dependent De-Acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 4141-4141.	0.6	0
95	Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG) Tj ETQq1 1 0.784314 rgBTi/Overload	0.6	0
96	Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN. <i>Blood</i> , 2015, 126, 1539-1539.	0.6	0
97	Average Time to Treatment in Lymphoma Patients Undergoing Ovarian Preservation: Experience from a Single Institution. <i>Blood</i> , 2015, 126, 2111-2111.	0.6	0
98	Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499. <i>Blood</i> , 2015, 126, 2702-2702.	0.6	0
99	Pidilizumab in the treatment of diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1361-1368.	1.4	20
100	Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. <i>Cancer</i> , 2014, 120, 1993-1999.	2.0	36
101	Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. <i>British Journal of Haematology</i> , 2014, 166, 514-520.	1.2	17
102	¹⁸ F-FDG PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem cell transplantation for relapsed and refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 165, 793-800.	1.2	41
103	An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>Blood</i> , 2014, 123, 837-842.	0.6	693
104	Non-Hodgkin's Lymphomas, Version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1282-1303.	2.3	144
105	Non-Hodgkin's Lymphomas, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 916-946.	2.3	38
106	High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender. <i>Blood</i> , 2014, 124, 3046-3046.	0.6	1
107	Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients (Pts) with Epstein Barr Virus (EBV)+ and/or CD30+ Lymphoma: Phase I Results of an Ongoing Phase I-II Study. <i>Blood</i> , 2014, 124, 3096-3096.	0.6	9
108	Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumor burden (HTB) indolent non-Hodgkin lymphoma (iNHL): A multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8545-8545.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014, 124, 864-864.	0.6	1
110	Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4199-4206.	0.8	433
111	Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 692-700.	0.8	176
112	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013, 31, 684-691.	0.8	256
113	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , 2013, 161, 76-86.	1.2	111
114	Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop. <i>Leukemia and Lymphoma</i> , 2013, 54, 1882-1890.	0.6	9
115	Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab. <i>Cancer</i> , 2013, 119, 3662-3671.	2.0	61
116	A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. <i>Annals of Oncology</i> , 2013, 24, 3076-3081.	0.6	45
117	Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies. <i>Cell Cycle</i> , 2013, 12, 133-144.	1.3	22
118	Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. <i>Leukemia and Lymphoma</i> , 2013, 54, 497-502.	0.6	16
119	Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era. <i>American Journal of Transplantation</i> , 2013, 13, 1512-1522.	2.6	150
120	A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. <i>British Journal of Haematology</i> , 2013, 163, 55-61.	1.2	39
121	Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. <i>British Journal of Haematology</i> , 2013, 163, 487-495.	1.2	64
122	Biomimetic, synthetic HDL nanostructures for lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2511-2516.	3.3	112
123	Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. <i>Leukemia and Lymphoma</i> , 2013, 54, 2155-2162.	0.6	12
124	Indolent lymphoma—why not to sprint at the start of a marathon. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 251-252.	12.5	1
125	MDCT of Chest, Abdomen, and Pelvis Using Attenuation-Based Automated Tube Voltage Selection in Combination With Iterative Reconstruction: An Inpatient Study of Radiation Dose and Image Quality. <i>American Journal of Roentgenology</i> , 2013, 201, 1075-1082.	1.0	50
126	Genetic heterogeneity of diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1398-1403.	3.3	494

#	ARTICLE	IF	CITATIONS
127	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553.	0.6	117
128	Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In Vivo. <i>PLoS ONE</i> , 2013, 8, e58491.	1.1	63
129	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. <i>Blood</i> , 2013, 122, 3060-3060.	0.6	5
130	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013, 122, 4277-4277.	0.6	3
131	Paradoxical Regulation of Hypoxia Inducible Factor-1 α (HIF-1 α) by Histone Deacetylase Inhibitor in Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2013, 8, e81333.	1.1	18
132	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90 α Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Journal of Clinical Oncology</i> , 2012, 30, 3119-3126.	0.8	86
133	Watchful Waiting in Low α Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. <i>Journal of Clinical Oncology</i> , 2012, 30, 3848-3853.	0.8	107
134	High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. <i>Leukemia and Lymphoma</i> , 2012, 53, 1113-1116.	0.6	38
135	Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493). <i>Leukemia and Lymphoma</i> , 2012, 53, 1137-1142.	0.6	4
136	Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. <i>Blood</i> , 2012, 119, 2093-2099.	0.6	88
137	A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. <i>Blood</i> , 2012, 119, 692-695.	0.6	138
138	Off-targeting off-targeted CD20 in cHL. <i>Blood</i> , 2012, 119, 4095-4096.	0.6	2
139	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. <i>Blood</i> , 2012, 120, 3280-3287.	0.6	188
140	The genetic landscape of mutations in Burkitt lymphoma. <i>Nature Genetics</i> , 2012, 44, 1321-1325.	9.4	517
141	Statin-dependent activation of protein kinase C δ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation. <i>Leukemia and Lymphoma</i> , 2012, 53, 1779-1784.	0.6	13
142	Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2776-2782.	0.8	162
143	Non-Hodgkin α Lymphomas, Version 3.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1487-1498.	2.3	29
144	Lack of benefit of central nervous system prophylaxis for diffuse large B α cell lymphoma in the rituximab era. <i>Cancer</i> , 2012, 118, 2944-2951.	2.0	78

#	ARTICLE	IF	CITATIONS
145	Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. <i>Antiviral Research</i> , 2012, 95, 49-56.	1.9	27
146	An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.. <i>Blood</i> , 2012, 120, 2656-2656.	0.6	0
147	Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.. <i>Blood</i> , 2012, 120, 2669-2669.	0.6	1
148	Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates. <i>Blood</i> , 2012, 120, 2024-2024.	0.6	0
149	Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. <i>Leukemia and Lymphoma</i> , 2011, 52, 1188-1199.	0.6	33
150	The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 1052-1061.	0.6	41
151	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 484-560.	2.3	161
152	Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1020-1058.	2.3	40
153	Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 563-571.	2.3	0
154	Curcumin nanodisks: formulation and characterization. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 162-167.	1.7	127
155	Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1537-1543.	0.6	47
156	Clinical, Morphologic, Immunophenotypic, and Molecular Cytogenetic Assessment of CD4 ⁺ /CD8 ⁺ T-Cell Large Granular Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2011, 136, 289-299.	0.4	51
157	Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era. <i>Blood</i> , 2011, 118, 2625-2625.	0.6	1
158	Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin's Lymphoma. <i>Blood</i> , 2011, 118, 4499-4499.	0.6	0
159	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 288-334.	2.3	233
160	Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. <i>Blood</i> , 2010, 116, e118-e127.	0.6	188
161	Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy. <i>Current Oncology Reports</i> , 2010, 12, 383-394.	1.8	133
162	Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. <i>British Journal of Haematology</i> , 2010, 150, 365-369.	1.2	16

#	ARTICLE	IF	CITATIONS
163	All <i>trans</i> retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 158-169.	1.2	40
164	Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 1038-1046.	0.8	290
165	Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of <i>Andrographis paniculata</i> . <i>Clinical Cancer Research</i> , 2010, 16, 4755-4768.	3.2	87
166	Hypoxia-Inducible Factor-1 \pm Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2010, 28, 1017-1024.	0.8	57
167	Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. <i>Leukemia and Lymphoma</i> , 2010, 51, 1163-1177.	0.6	13
168	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 443-468.	2.0	60
169	A Randomized Phase III Trial of ABVD Vs. Stanford V + ¹⁸ F Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Blood</i> , 2010, 116, 415-415.	0.6	18
170	Ethnicity Significantly Influences Incidence Patterns and Predicts Mortality: Adult Hodgkin Lymphoma (HL) In the United States (US). <i>Blood</i> , 2010, 116, 2683-2683.	0.6	0
171	Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines. <i>Anticancer Research</i> , 2010, 30, 1131-6.	0.5	3
172	Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways. <i>Journal of Biological Chemistry</i> , 2009, 284, 2080-2087.	1.6	152
173	Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1653-1659.	0.8	101
174	Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1607-1614.	0.8	264
175	PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- κ B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells. <i>Clinical Cancer Research</i> , 2009, 15, 3354-3365.	3.2	92
176	The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial. <i>Clinical Cancer Research</i> , 2009, 15, 6462-6471.	3.2	14
177	Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. <i>British Journal of Haematology</i> , 2009, 145, 34-39.	1.2	72
178	Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?. <i>Bone Marrow Transplantation</i> , 2009, 43, 301-305.	1.3	6
179	Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 1434-1441.	0.6	31
180	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009, 113, 4834-4840.	0.6	829

#	ARTICLE	IF	CITATIONS
181	Glutathione Depletion Enhances Arsenic Trioxide-Induced Apoptosis in Lymphoma Cells through Mitochondrial and Caspase-Independent Mechanisms.. Blood, 2009, 114, 2708-2708.	0.6	1
182	The Novel 2nd Generation Small Molecule MEK Inhibitor, AZD-6244, Induces Cell Death in Lymphoma Cells Lines, Primary Cells, and in a Human Lymphoma Xenograft Model.. Blood, 2009, 114, 285-285.	0.6	2
183	PX-478, a Novel Small Molecule Inhibitor of Hypoxia Inducible Factor-1 (HIF-1) Downregulates HIF and Induces Cytotoxicity in Diffuse Large B Cell Lymphoma Cells.. Blood, 2009, 114, 2713-2713.	0.6	1
184	Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database.. Blood, 2009, 114, 1387-1387.	0.6	15
185	A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. British Journal of Haematology, 2008, 140, 385-393.	1.2	47
186	Hypoxia inducible factor- α activation in lymphoma and relationship to the thioredoxin family. British Journal of Haematology, 2008, 141, 676-680.	1.2	40
187	CD23+ Mantle Cell Lymphoma. American Journal of Clinical Pathology, 2008, 130, 166-177.	0.4	54
188	Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder. Transplantation, 2008, 86, 215-222.	0.5	113
189	The Broad Spectrum HDAC Inhibitor PCI-24781 Induces Caspase- and ROS-Dependent Apoptosis and is Synergistic with Bortezomib in Lymphoma. Nature Precedings, 2008, , .	0.1	0
190	Triggered Release of Nanoparticulate Arsenic Trioxide for Treatment of Malignant Lymphomas: Preclinical Studies. Blood, 2008, 112, 4989-4989.	0.6	0
191	Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy. Journal of Clinical Oncology, 2007, 25, 4285-4292.	0.8	142
192	Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Annals of Oncology, 2007, 18, 679-688.	0.6	26
193	A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Annals of Oncology, 2007, 18, 1216-1223.	0.6	103
194	Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's Lymphoma. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 684-691.	0.7	35
195	Sustained Hematologic and Central Nervous System Remission with Single-Agent Denileukin Difitox in Refractory Adult T-Cell Leukemia/Lymphoma. Clinical Lymphoma and Myeloma, 2007, 7, 472-474.	1.4	10
196	Weight-Based Dosing of Yttrium 90 Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma and Myeloma, 2007, 7, 514-517.	1.4	7
197	Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer, 2007, 109, 1532-1535.	2.0	197
198	Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer, 2007, 109, 1804-1810.	2.0	164

#	ARTICLE	IF	CITATIONS
199	Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. <i>Bone Marrow Transplantation</i> , 2007, 40, 451-456.	1.3	205
200	G-CSF is not necessary to maintain over 99% dose?intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. <i>British Journal of Haematology</i> , 2007, 137, 545-552.	1.2	71
201	Motexafin Gadolinium (MGD) Induces Oxidant Stress and Downregulates Both Pro and Anti-Oxidant Genes in the Ramos Lymphoma Cell Line: Signaling through p53 Mediated Pathways.. <i>Blood</i> , 2007, 110, 4429-4429.	0.6	0
202	Hypoxia-Inducible Factor-Alpha (HIF-1 α) Activation in Non-Hodgkin's Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).. <i>Blood</i> , 2007, 110, 3587-3587.	0.6	0
203	Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum. <i>Leukemia and Lymphoma</i> , 2006, 47, 1352-1359.	0.6	18
204	Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. <i>Leukemia and Lymphoma</i> , 2006, 47, 998-1005.	0.6	108
205	Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 629-636.	0.6	83
206	Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 37, 553-557.	1.3	18
207	Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. <i>Bone Marrow Transplantation</i> , 2006, 37, 997-1001.	1.3	75
208	Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?. <i>Bone Marrow Transplantation</i> , 2006, 38, 95-100.	1.3	52
209	Comparison of Out-of-Pocket Costs and Quality of Life (QOL) for Patients (pts) with Hodgkin's Disease (HD), Indolent Non-Hodgkin's Lymphoma (INHL) and Aggressive Non-Hodgkin's Lymphoma (ANHL).. <i>Blood</i> , 2006, 108, 3332-3332.	0.6	0
210	Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. <i>Blood</i> , 2005, 105, 1265-1273.	0.6	71
211	Flu redux and RIT: friendly fire in the treatment of low-grade lymphoma. <i>Blood</i> , 2005, 105, 4543-4544.	0.6	2
212	Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?. <i>Bone Marrow Transplantation</i> , 2005, 35, 243-246.	1.3	33
213	Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF. <i>Bone Marrow Transplantation</i> , 2005, 36, 663-666.	1.3	9
214	Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies. <i>Current Treatment Options in Oncology</i> , 2005, 6, 289-296.	1.3	15
215	Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 4390-4398.	0.8	143
216	Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL.. <i>Blood</i> , 2005, 106, 2435-2435.	0.6	14

#	ARTICLE	IF	CITATIONS
217	Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 4758-4758.	0.6	1
218	Dramatic and Sustained Hematologic Complete Remission with Denileukin Diftitox (ONTAK®) in a Patient with Refractory Adult T-Cell Leukemia (ATL).. Blood, 2005, 106, 4638-4638.	0.6	0
219	Combination of Motexafin Gadolinium (MGd) with 90Y Ibritumomab Tiuxetan (Zevalin®); Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Rituximab-Refractory Follicular Non- Hodgkinâ€™s Lymphoma (NHL).. Blood, 2005, 106, 2450-2450.	0.6	0
220	Allogeneic Stem Cell Transplantation (AlloSCT) for Relapsed Hodgkinâ€™s Lymphoma (HL) Following Autologous Stem Cell Transplantation (AuSCT): Improved Progression-Free Survival (PFS) in Patients with Graft vs Host-Disease (GvHD) Suggests a Graft vs Lymphoma (GVL) Effect.. Blood, 2005, 106, 5455-5455.	0.6	0
221	A green tea component, catechin, rapidly induces apoptosis of myeloid leukemic cells via modulation of reactive oxygen species production in vitro and inhibits tumor growth in vivo. Haematologica, 2005, 90, 290.	1.7	1
222	Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent. Clinical Cancer Research, 2004, 10, 1481-1491.	3.2	46
223	Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood, 2004, 103, 4429-4431.	0.6	181
224	Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?. Bone Marrow Transplantation, 2004, 33, 161-164.	1.3	12
225	How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?. Bone Marrow Transplantation, 2004, 33, 715-719.	1.3	5
226	Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplantation, 2004, 34, 561-571.	1.3	91
227	Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 478-481.	0.7	27
228	A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL). Leukemia and Lymphoma, 2004, 45, 2269-2273.	0.6	61
229	Yttrium 90â€™-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma. Clinical Lymphoma and Myeloma, 2004, 5, 98-101.	2.1	117
230	Antilymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan Are Feasible in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the Literature. Clinical Lymphoma and Myeloma, 2004, 5, 202-204.	2.1	37
231	Radioimmunotherapy in Non-Hodgkin's Lymphoma: Trials of Yttrium 90â€™-Labeled Ibritumomab Tiuxetan and Beyond. Clinical Lymphoma and Myeloma, 2004, 5, S11-S15.	2.1	4
232	Efficacy and safety of radioimmuno-therapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Seminars in Oncology Nursing, 2004, 20, 8-13.	0.7	2
233	90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.. Blood, 2004, 104, 1162-1162.	0.6	11
234	Feasibility of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy for Non-Hodgkinâ€™s Lymphoma in a Patient with Chronic Renal Failure.. Blood, 2004, 104, 4642-4642.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Evaluation of Baseline Body-Weight Dosing of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).. Blood, 2004, 104, 2634-2634.	0.6	0
236	Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).. Blood, 2004, 104, 2629-2629.	0.6	0
237	Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (zevalin). Seminars in Oncology, 2003, 30, 23-28.	0.8	6
238	Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?. Bone Marrow Transplantation, 2003, 31, 861-864.	1.3	17
239	Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. Blood, 2003, 102, 297-302.	0.6	46
240	Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2003, 21, 1263-1270.	0.8	278
241	Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood, 2002, 99, 4336-4342.	0.6	257
242	Randomized Controlled Trial of Yttrium-90 Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2002, 20, 2453-2463.	0.8	1,069
243	Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2002, 20, 3262-3269.	0.8	624
244	Secondary Acute Myelogenous Leukemia with MLL Gene Rearrangement Following Radioimmunotherapy (RAIT) for Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2002, 43, 2145-2149.	0.6	15
245	Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Seminars in Oncology, 2002, 29, 87-92.	0.8	56
246	Burkitt's and Burkitt-like Lymphoma. Current Treatment Options in Oncology, 2002, 3, 291-305.	1.3	18
247	Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplantation, 2002, 30, 517-519.	1.3	42
248	Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 Å– 109/l neutrophils on 3 consecutive days to define myeloid recovery. Bone Marrow Transplantation, 2002, 30, 749-752.	1.3	17
249	Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clinical Cancer Research, 2002, 8, 566-72.	3.2	64
250	Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Seminars in Oncology, 2002, 29, 87-92.	0.8	8
251	CD34+ cell collection efficiency does not correlate with the pre-leukapheresis hematocrit. Bone Marrow Transplantation, 2001, 28, 597-601.	1.3	19
252	Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, andâ€%.â€%.â€%.. Bone Marrow Transplantation, 2001, 28, 811-812.	1.3	12

#	ARTICLE	IF	CITATIONS
253	Thrombotic Microangiopathy in the Cancer Patient. <i>Acta Haematologica</i> , 2001, 106, 52-56.	0.7	77
254	Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20 ⁺ B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3793-3803.	0.8	525
255	A Phase II Trial of 200% ProMACE-CytaBOM in Patients With Previously Untreated Aggressive Lymphomas: Analysis of Response, Toxicity, and Dose Intensity. <i>Blood</i> , 1999, 94, 3307-3314.	0.6	31
256	Evaluation of Mitoguazone in Patients with Refractory Chronic Lymphocytic Leukemia: A Phase II Study (P-H482) of the Eastern Cooperative Oncology Group. <i>Leukemia and Lymphoma</i> , 1999, 35, 375-377.	0.6	3
257	Thrombotic Microangiopathy Manifesting as Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome in the Cancer Patient. <i>Seminars in Thrombosis and Hemostasis</i> , 1999, 25, 217-221.	1.5	78
258	Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-hodgkin's lymphoma. , 1998, 82, 957-964.		24
259	Adoptive Immunotherapy for Leukemia: Donor Lymphocytes Transduced with the Herpes Simplex Thymidine Kinase Gene for Remission Induction. Human Gene Therapy Research Institute, Des Moines, Iowa, and Northwestern University School of Medicine, Chicago, Illinois. <i>Human Gene Therapy</i> , 1998, 9, 115-134.	1.4	38
260	Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-hodgkin's lymphoma. , 1998, 82, 957.		3
261	Management of Early-Stage Hodgkin's Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 235-240.	0.6	1
262	Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. <i>Cancer</i> , 1995, 75, 865-873.	2.0	24
263	Inhibition of cytolytic T lymphocyte activity by oxysterols. <i>Lipids</i> , 1994, 29, 657-660.	0.7	22
264	A VM 26-based regimen for patients with previously untreated non-Hodgkin lymphoma. Prolonged disease-free survival in patients younger than 60 years of age: A phase II trial of the eastern cooperative oncology group. <i>Cancer</i> , 1993, 71, 464-470.	2.0	3
265	Bacterial Phosphatidylcholine-Preferring Phospholipase C Reversibly Inhibits the Membrane Component of the NADPH Oxidase in Human Polymorphonuclear Leukocytes: Implications for Host Defense. <i>Cellular Immunology</i> , 1993, 152, 582-593.	1.4	4
266	Phase I Trial of the Diphtheria Toxin/Interleukin-2 Fusion Protein DAB486IL-2: Efficacy in Mycosis Fungoides and Other Non-Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 1993, 11, 369-377.	0.6	35
267	Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 1992, 327, 1342-1349.	13.9	318
268	Inhibition of NK cell-mediated cytotoxicity by oxysterols. <i>Cellular Immunology</i> , 1992, 139, 541-549.	1.4	34
269	Treatment of Advanced Refractory Lymphomas with a Combination of Carmustine, Bleomycin, Teniposide, Dexamethasone, and Cisplatin (The BBVDD Regimen). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1991, 14, 579.	0.6	2
270	Scavenging of Superoxide Anion by Phosphorylethanolamine: Studies in Human Neutrophils and in a Cell Free System. <i>Free Radical Research Communications</i> , 1991, 15, 65-71.	1.8	9

#	ARTICLE	IF	CITATIONS
271	Inhibition of polymorphonuclear leukocyte oxidative metabolism by exogenous phospholipase C. Cellular Immunology, 1990, 128, 503-515.	1.4	2
272	Inhibition of Human Polymorphonuclear Leukocyte Respiratory Burst Activity and Aggregation by 6-Ketocholestanol. Free Radical Research Communications, 1990, 8, 185-193.	1.8	4
273	Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A phase ii study by the illinois cancer council. Cancer, 1985, 56, 1311-1315.	2.0	21
274	Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A phase ii study by the illinois cancer council. , 1985, 56, 1311.		1
275	Benign hepatic cyst in a patient on antiestrogen therapy for metastatic breast cancer. Cancer, 1982, 50, 1882-1883.	2.0	3
276	Bronchogenic carcinoma located in the aortic window. Journal of Thoracic and Cardiovascular Surgery, 1982, 83, 551-562.	0.4	12
277	Small-cell carcinoma of the lung: A five-year experience with combined modality therapy. Cancer, 1980, 46, 2550-2556.	2.0	16
278	Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: Response to chemotherapy in two cases. Medical and Pediatric Oncology, 1979, 7, 111-116.	1.0	1
279	Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide coated nanoparticles. Blood Advances, 0, , .	2.5	2